The FSHD Society extends our support to the myotonic dystrophy community after the announcement that Novartis’ Phase 3 HARBOR trial of del-desiran in myotonic dystrophy did not meet its primary … Continue reading Novartis’ Phase 3 HARBOR Trial Results: An Update for the FSHD Community